Therapeutic potential of the dual EGFR/HER2 inhibitor AZD8931 in circumventing endocrine resistance

By Morrison Gladys   Fu Xiaoyong   Shea Martin   Nanda Sarmistha   Giuliano Mario   Wang Tao   Klinowska Teresa   Osborne C.   Rimawi Mothaffar   Schiff Rachel  

Breast Cancer Research and Treatment, Vol. 144, Iss. 2, 2014-04 ,pp. : 263-272

Springer Publishing Company

Access to resources Recommend Favorite

EGFR inhibitors in non-small cell lung cancer (NSCLC): the emerging role of the dual irreversible EGFR/HER2 inhibitor BIBW 2992

By Spicer James  

Targeted Oncology, Vol. 5, Iss. 4, 2010-12 ,pp. : 245-255

Springer Publishing Company

Access to resources Recommend Favorite

Coexpression patterns of EGFR, HER2, HER3 and HER4 in non-melanoma skin cancer

By Krahn G.   Leiter U.   Kaskel P.   Udart M.   Utikal J.   Bezold G.   Peter R.U.  

European Journal of Cancer, Vol. 37, Iss. 2, 2001-01 ,pp. : 251-259

Elsevier

Access to resources Recommend Favorite

EGFR/HER2 inhibitors effectively reduce the malignant potential of MDR breast cancer evoked by P-gp substrates in vitro and in vivo

By              

Oncology Reports, Vol. 35, Iss. 2, 2016-01 ,pp. : 771-778

Spandidos Publications

Access to resources Recommend Favorite

HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib

By Valabrega Giorgio  

Breast Cancer Research and Treatment, Vol. 130, Iss. 1, 2011-11 ,pp. : 29-40

Springer Publishing Company

Access to resources Recommend Favorite